Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dysrhythmias IV: Characteristics of Bradyarrhythmias01:18

Dysrhythmias IV: Characteristics of Bradyarrhythmias

137
Bradyarrhythmias are cardiac rhythm disorders characterized by a slower-than-normal heart rate, typically defined as fewer than 60 beats per minute. Some of which are discussed here:Sinus BradycardiaSinus bradycardia presents a heart rate lower than 60 beats per minute, with a regular rhythm originating from the SA node. The ECG typically shows normal P waves preceding each QRS complex, a normal PR interval (0.12 to 0.20 seconds), and a normal QRS duration (0.06 to 0.10 seconds).First-Degree AV...
137
Disturbances in Heart Rhythm01:29

Disturbances in Heart Rhythm

1.5K
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
1.5K
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

133
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
133
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

193
Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
193
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

1.1K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
1.1K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

963
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
963

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Role of Inflammatory Biomarkers in Peripheral Arterial Disease: A Comprehensive Review of Prognostic and Therapeutic Implications.

Biomolecules·2026
Same author

Age-Dependent Inflammatory, Lipid, and Echocardiographic Phenotypes in Acute Myocardial Infarction: Associations with In-Hospital Adverse Clinical Events.

Biomedicines·2026
Same author

Clinical Profiles and Prognostic Patterns in Critically Ill Cardiac Patients Requiring Invasive Mechanical Ventilation: A Five-Year Retrospective Cohort Study.

Diagnostics (Basel, Switzerland)·2026
Same author

Left Atrial Myxoma Surgery in Cryoglobulinemic Vasculitis Associated with Hepatitis B: A Clinical Case Report.

Reports (MDPI)·2026
Same author

Type A Aortic Dissection: From Diagnosis to Cardiac Rehabilitation.

Journal of clinical medicine·2026
Same author

Systemic Inflammation and Structural Retinal Damage on OCT in Acute Non-Arteritic Central Retinal Artery Occlusion-A Retrospective Study.

International journal of molecular sciences·2026

Related Experiment Video

Updated: Oct 2, 2025

Reduction of Iatrogenic Atrial Septal Defects with an Anterior and Inferior Transseptal Puncture Site when Operating the Cryoballoon Ablation Catheter
08:00

Reduction of Iatrogenic Atrial Septal Defects with an Anterior and Inferior Transseptal Puncture Site when Operating the Cryoballoon Ablation Catheter

Published on: June 15, 2015

14.1K

Beta-Blocker-Related Atrioventricular Conduction Disorders-A Single Tertiary Referral Center Experience.

Dragoș Traian Marius Marcu1, Cristina Andreea Adam2, Dan-Mihai Dorobanțu3,4

  • 1Department of Internal Medicine, University of Medicine and Pharmacy "Grigore T. Popa" Iași, 700115 Iași, Romania.

Medicina (Kaunas, Lithuania)
|February 25, 2022
PubMed
Summary

Beta-blocker use is linked to specific bradyarrhythmia types like slow atrial fibrillation and sick sinus syndrome, rather than severe atrioventricular blocks. This finding helps understand drug-related bradycardia presentations and associated patient factors.

Keywords:
adverse drug reactionsbeta-blockerbradyarrhythmiaconduction disorderrisk factor

More Related Videos

Robotic Ablation of Atrial Fibrillation
11:21

Robotic Ablation of Atrial Fibrillation

Published on: May 29, 2015

19.8K
Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

1.0K

Related Experiment Videos

Last Updated: Oct 2, 2025

Reduction of Iatrogenic Atrial Septal Defects with an Anterior and Inferior Transseptal Puncture Site when Operating the Cryoballoon Ablation Catheter
08:00

Reduction of Iatrogenic Atrial Septal Defects with an Anterior and Inferior Transseptal Puncture Site when Operating the Cryoballoon Ablation Catheter

Published on: June 15, 2015

14.1K
Robotic Ablation of Atrial Fibrillation
11:21

Robotic Ablation of Atrial Fibrillation

Published on: May 29, 2015

19.8K
Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

1.0K

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Medicine

Background:

  • Drug-related bradyarrhythmia is a significant adverse event in beta-blocker users, often leading to hospitalization.
  • The specific bradyarrhythmia presentations associated with beta-blocker use and their relationship with other risk factors are not fully understood.

Purpose of the Study:

  • To evaluate the association between beta-blocker use and different types of atrioventricular (AV) conduction disorders in patients presenting with symptomatic bradycardia.

Main Methods:

  • A retrospective cohort study involving 596 patients with symptomatic bradyarrhythmia.
  • Analysis of demographics, clinical, and paraclinical parameters, comparing patients on beta-blockers (n=253) versus those not (n=343).
  • Multivariate regression analysis was employed to identify factors associated with beta-blocker use.

Main Results:

  • Beta-blocker use was associated with female gender, emergency admission, dilated cardiomyopathy, lower ejection fraction, mitral stenosis, chronic kidney disease, higher potassium levels, and wider QRS duration.
  • Slow atrial fibrillation (OR=4.2), sick sinus syndrome (OR=2.8), and sinus bradycardia/pauses (OR=32.9) were more likely associated with beta-blocker use compared to third-degree AV block.

Conclusions:

  • Beta-blocker use is more frequently associated with slow atrial fibrillation, sick sinus syndrome, and sinus bradycardia/pauses.
  • These associations persist after adjusting for various patient characteristics, including gender, admission type, ECG findings, comorbidities, cardiac function, and lab results.